Mezzion Pharma Co., Ltd.

Dong-a Pharmtech Co., Ltd.

Dong-a Pharmaceutical Co., Ltd

Seul Min Choi

Moohi Yoo

Ji Hye Lee

Sung Pil Choi

Soon-Hoe Kim

Byoung Ok Ahn

Kyung Koo Kang

Byong Ok Ahn

Jae Young Yu

Ji Hyun Sung

Hyun Jung Kim

Ju Mi Kim

Eunjin Kim

The present invention relates to the pharmaceutical composition for prevention and treatment of liver diseases containing pyrazolopyrimidine derivative as an active ingredient. According to the present invention, pyrazolopyrimidine derivative has an excellent effect on inhibiting collagen synthesis in hepatic stellate cells and acts directly on the portal vein. Particularly, it may increase the diameter and the amount of blood flow of the portal vein, and finally decrease the pressure thereof. Therefore, pyrazolopyrimidine derivative can be used advantageously for prevention and treatment of hepatic fibrosis, liver cirrhosis caused by hepatic fibrosis, portal hypertension and various complications caused by portal hypertension. In addition, pyrazolopyrimidine derivative according to the present invention can reduce dosing frequency because of its long half-life, and therefore, has an advantage to improve the drug compliance of patients suffering from chronical liver diseases.

Agent for treatment of liver diseases containing pyrazolopyrimidinone derivative

The present invention relates to an agent for preventing and treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) associated with BPH and a relaxant for relaxing urethral smooth muscle or prostatic smooth muscle comprising a pyrazolopyrimidinone compound as an effective ingredient. The agent in accordance with the present invention can provide nitric oxides by inhibiting the activity of PDE-5 that decomposes c-GMP, and the provided nitric oxides relax the urethral smooth muscle or the prostatic smooth muscle to lower the intraurethral pressure (IUP), thus treating BPH and LUTS associated with BPH. Furthermore, the time required for reaching a maximum blood concentration is shorter and the half-life is longer than the other PDE-5 inhibitors, thus reducing the frequency of administration. Moreover, the agent of the invention causing few side effects can be efficiently used as a safe drug.

Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound

Growing community of inventors

Suwon-si, South Korea

Seul Min Choi